[Intra-patient cancer heterogeneity and sacituzumab-govitecan efficacy.]

Q3 Medicine
Andrea Fontana, Federica Pantaleo
{"title":"[Intra-patient cancer heterogeneity and sacituzumab-govitecan efficacy.]","authors":"Andrea Fontana, Federica Pantaleo","doi":"10.1701/4357.43480","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced triple negative breast cancer (TNBC) represents a challenging clinical condition with limited therapeutics opportunities. However, recently, a new antibody drug conjugated, sacituzumab govitecan, demonstrated a relevant clinical efficacy in this setting of patients. In this report we describe the case of a patient with TNBC diagnosed at the metastatic level when the primary breast tumour presented overexpression of ER end PgR. An important tumoral heterogeneity has been described in breast cancer during its natural evolution and for that reason is important to perform metastatic lesions re-biopsy, when feasible, in order to re-evaluate the biological characteristics and define the optimal therapeutic strategy.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 10","pages":"57e-60e"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4357.43480","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Advanced triple negative breast cancer (TNBC) represents a challenging clinical condition with limited therapeutics opportunities. However, recently, a new antibody drug conjugated, sacituzumab govitecan, demonstrated a relevant clinical efficacy in this setting of patients. In this report we describe the case of a patient with TNBC diagnosed at the metastatic level when the primary breast tumour presented overexpression of ER end PgR. An important tumoral heterogeneity has been described in breast cancer during its natural evolution and for that reason is important to perform metastatic lesions re-biopsy, when feasible, in order to re-evaluate the biological characteristics and define the optimal therapeutic strategy.

[患者内部癌症异质性与Sacituzumab-Govitecan疗效]
晚期三阴性乳腺癌(TNBC)是一种具有挑战性的临床病症,治疗机会有限。然而,最近一种新型抗体药物--sacituzumab govitecan--在这类患者中显示出了相关的临床疗效。在本报告中,我们描述了一例被诊断为转移性 TNBC 的患者,其原发乳腺肿瘤呈现 ER 末端 PgR 的过度表达。在乳腺癌的自然演化过程中,肿瘤的异质性非常重要,因此,在可行的情况下,对转移病灶进行再次活检非常重要,以便重新评估其生物学特征并确定最佳治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信